Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
Summary
The team has made remarkable progress since inception, and we believe Scorpions targeted approach may be able to overcome the selectivity challenges that plague existing treatment options, ultimately providing better outcomes to patients by offering improvements in both efficacy and safety. In preclinical models, STX-478 demonstrated robust activity across a range of PI3K mutations while sparing wild-type PI3K inhibition in normal tissues; previous generations of non-selective PI3K inhibitors have limited patient benefit due to these on-target toxicities. Scorpions Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally advanced or metastatic HR+/HER2- breast cancer and other solid tumors driven by PI3K mutations. To learn more about the first-in-human trial of STX-478, please visit this page.Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer. Scorpion has built a proprietary and fully-integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets.